|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Medical University of South Carolina |
|---|---|
| Collaborator: |
National Institutes of Health (NIH) |
| Information provided by: | Medical University of South Carolina |
| ClinicalTrials.gov Identifier: | NCT00576693 |
Purpose
PRIMARY HYPOTHESIS:
Compared with intensive medical therapy alone, intracranial angioplasty and stenting combined with intensive medical therapy will decrease the risk of the primary endpoint by 35% over a mean follow-up of two years in high-risk patients (patients with 70% - 99% intracranial stenosis who had a TIA or stroke within 30 days prior to enrollment) with symptomatic stenosis of a major intracranial artery.
SUMMARY:
The best treatment for prevention of another stroke or TIA in patients with narrowing of one of the arteries in the brain is uncertain. A common treatment is the use of anti-clotting medications to prevent blood clots from forming in the narrowed vessel. There are a variety of medicines used for this purpose. These medications are usually taken for the rest of a patient's life.
However, a treatment that has been used successfully together with anti-clotting medications in patients with narrowing of the blood vessels of the heart is now being studied in the blood vessels of the brain. This treatment is called stenting.
Recent research has also indicated a benefit in prevention of recurring stroke by Intensive Medical Therapy, which is defined as treating risk factors for stroke like high blood pressure, elevated LDL (low density lipids - the "bad" form of cholesterol) and diabetes. The purpose of this study is to compare the safety and effectiveness of either Intensive Medical Therapy PLUS Stenting or Intensive Medical Therapy ONLY in preventing stroke, heart attacks or death.
The study will enroll patients over a 5 year period. Each participant will be involved in the study for a minimum of 1 year and a maximum of 3 years.
Fifty different medical centers in the United States are part of this study. Both the Clinical Coordinating Center and the Statistical Coordinating Center for the entire study will be located at Emory University.
| Condition | Intervention | Phase |
|---|---|---|
|
Ischemic Stroke |
Device: Wingspan intracranial stent with Gateway balloon Other: Intensive Medical Therapy |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Parallel Assignment |
| Official Title: | Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis |
| Estimated Enrollment: | 764 |
| Study Start Date: | October 2008 |
| Estimated Study Completion Date: | October 2013 |
| Estimated Primary Completion Date: | October 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Experimental
Stenting arm
|
Device: Wingspan intracranial stent with Gateway balloon
Wingspan intracranial stent with Gateway balloon
Other: Intensive Medical Therapy
Management of blood pressure, lipids, and other risk factors for vascular events.Patients treated with lipid-lowering agents, antihypertensives, aspirin, glucose-lowering agents as indicated by their individual medical condition.
|
|
2: Experimental
Medical arm
|
Other: Intensive Medical Therapy
Management of blood pressure, lipids, and other risk factors for vascular events.Patients treated with lipid-lowering agents, antihypertensives, aspirin, glucose-lowering agents as indicated by their individual medical condition.
|
Eligibility| Ages Eligible for Study: | 30 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA
TIA or non-severe stroke within 30 days of enrollment attributed to 70-99% stenosis of a major intracranial artery (carotid artery, MCA stem (M1), vertebral artery, or basilar artery)
• may be diagnosed by TCD, MRA, or CTA to qualify for angiogram performed as part of the study protocol but must be confirmed by catheter angiography for enrollment in the trial
Age ≥ 30 years and ≤ 80 years.
• Patients 30-49 years are required to meet at least one additional criteria (i-vi) provided in the table below to qualify for the study. This additional requirement is to increase the likelihood that the symptomatic intracranial stenosis in patients 30-49 years is atherosclerotic.
i. insulin dependent diabetes for at least 15 years ii. at least 2 of the following atherosclerotic risk factors: hypertension (BP > 140/90 or on antihypertensive therapy); dyslipidemia (LDL > 130 mg /dl or HDL < 40 mg/dl or fasting triglycerides > 150 mg/dl or on lipid lowering therapy); smoking; non-insulin dependent diabetes or insulin dependent diabetes of less than 15 years duration; family history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery in parent or sibling who was < 55 years of age for men or < 65 for women at the time of the event ii. history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease iv. any stenosis of an extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by non-invasive vascular imaging or catheter angiography and is considered atherosclerotic v. aortic arch atheroma documented by non-invasive vascular imaging or catheter angiography vi. any aortic aneurysm documented by non-invasive vascular imaging or catheter angiography that is considered atherosclerotic
EXCLUSION CRITERIA
Contacts and Locations| Contact: Bethany F Lane, RN,BSN,CCRC | 678-429-1012 | bethany.lane@emory.edu |
| Contact: Rie Calcaterra | 678-557-6466 | calcater@musc.edu |
Show 57 Study Locations| Principal Investigator: | Marc I Chimowitz, MBChB | Medical University of South Carolina |
More Information
| Responsible Party: | Medical University of South Carolina ( Marc Chimowitz, MBChB ) |
| Study ID Numbers: | R01NS058728-01A1, R01NS058728-01A1 |
| Study First Received: | December 7, 2007 |
| Last Updated: | February 12, 2009 |
| ClinicalTrials.gov Identifier: | NCT00576693 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
ischemic stroke intracranial stenting vascular risk factor management |
|
Cerebral Infarction Stroke Nervous System Diseases Vascular Diseases Central Nervous System Diseases Cardiovascular Agents Brain Diseases |
Antihypertensive Agents Cerebrovascular Disorders Pharmacologic Actions Therapeutic Uses Brain Ischemia Cardiovascular Diseases Brain Infarction |